Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 0.86 |
| ▸ | EGFR | P00533 | 1/20 | 0.86 |
| ▸ | LCK | P06239 | 1/20 | 0.86 |
| ▸ | LYN | P07948 | 1/20 | 0.86 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-343 SCHEMBL2037260 | 0.92 | SYK (1.00) | SYKJAK2EGFRLCKLYN | |
| R-343 SCHEMBL31060361 | 0.92 | SYK (1.00) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL13007740 | 0.91 | SYK (0.83) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL1198317 | 0.87 | SYK (0.77) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL12872816 | 0.86 | SYK (0.88) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL3833116 | 0.85 | SYK (0.75) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL3837517 | 0.85 | SYK (0.73) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL27613047 | 0.84 | SYK (0.72) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL658794 | 0.84 | SYK (0.71) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL29794592 | 0.83 | SYK (1.00) | SYKJAK2EGFRLCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534286-B1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2009-12-09 | — | — | EP | claimed |
| US-8246984-B2 | Formulation of insoluble small molecule therapeutics in lipid-based carriers | RIGEL PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8246984-B2 | Formulation of insoluble small molecule therapeutics in lipid-based carriers | RIGEL PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090291129-A1 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS | RIGEL PHARMACEUTICALS, INC. | 2009-11-26 | — | — | US | disclosed |
| US-20090291129-A1 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS | RIGEL PHARMACEUTICALS, INC. | 2009-11-26 | — | — | US | disclosed |
| WO-2007111720-A2 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291129-A1 | FORMULATION OF INSOLUBLE SMALL MOLECULE THERAPEUTICS IN LIPID-BASED CARRIERS | ABCB4, ABHD16A, SGMS1 | SYK 2642/4885JAK2 1458/4885EGFR 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.